Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Schick Technologies (SCHK) -- Ignore unavailable to you. Want to Upgrade?

To: EURO who wrote (58)	4/22/1998 10:30:00 PM
From: Steve Rolfe	Read Replies (1) \| Respond to of 83

SCHICK TECHNOLOGIES INC. (SCHK) Misc. Info Broker Recommendations Rating # Brokers Strong Buy 2 Buy 1 Hold 0 Under Perform 0 Sell 0 Consensus (Mean) 1.333* *(1 = Strong Buy, 5 = Sell) Rating Changes # Ratings # Ratings upgraded last month 0 # Ratings downgraded last month 0 Quarterly EPS Estimates Period EPS Current Fiscal Quarter (03/1998) $0.11 Next Fiscal Quarter (06/1998) $0.14 Annual EPS Estimates Period EPS Current Fiscal Year (1998) $0.28 Next Fiscal Year (1999) $0.79 Long Term Growth Rate Forecast Expected annual increase in operating earnings over the next full business cycle (3-5 years) N/A Latest Reported Quarterly EPS Quarter Ending EPS 12/1997 $0.12 09/1997 $0.10 06/1997 $-0.01 Latest Reported Annual EPS Fiscal Year Ending EPS 03/1997 $-0.04

To: EURO who wrote (58)	4/22/1998 10:54:00 PM
From: Steve Rolfe	Read Replies (1) \| Respond to of 83

Also from Pacific Growth Equities:(April 8th) Schick Technologies, Inc. (SCHK:Nasdaq) $26.88 CDR (dental) sales continue to be robust in a relatively flat seasonal quarter. accuDEXA sales are showing that the initial product launch is a success. Our estimate in revenue for both CDR and accuDEXA sales appear low going forward. Schick still expects to partner its spot mammography device to distribution partners, and it could hit the market by CY:98. We recently raised our revenue and EPS estimates for FY:98-FY:00 to $39.2 million, $71.0 million and $101.1 million. Corresponding EPS estimates (all fully taxed) were raised to $0.23, $0.78 and $1.26. Our model still assumes no U.S. military sales, no panoramic option sales, and no full scale mammography system sales. Estimate revisions are based on the robust sales of both dental and accuDEXA systems. Investors should become more comfortable with the greater visibility into forecasts for FY:99 and FY:00, leading to a stock price that grows in line with the Company's 50-100% growth rate. Our 12-18 month target price is $50 per share. Strong Buy.